AAA
Affinity Asset Advisors Portfolio holdings
AUM
$676M
This Quarter Return
+90.1%
1 Year Return
+29.75%
3 Year Return
+452.89%
5 Year Return
–
10 Year Return
–
AUM
$163M
AUM Growth
–
Cap. Flow
+$159M
Cap. Flow
% of AUM
97.52%
Top 10 Holdings %
Top 10 Hldgs %
58.02%
Holding
61
New
55
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
|
$29.6M |
| 2 |
Curis
CRIS
|
$11.9M |
| 3 |
BridgeBio Pharma
BBIO
|
$11M |
| 4 |
Kura Oncology
KURA
|
$8.49M |
| 5 |
VINC
Vincerx Pharma, Inc. Common Stock
VINC
|
$8.43M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 95.13% |
| 2 | Consumer Staples | 0.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Madrigal Pharmaceuticals
MDGL
$9.7B
| $556K | 0.29% |
+5,000
| New | +$556K |
|
52
CRISPR Therapeutics
CRSP
$4.82B
| $536K | 0.28% |
+3,500
| New | +$536K |
|
|
CEREW
53
DELISTED
Cerevel Therapeutics Holdings, Inc. Warrant
CEREW
| $409K | 0.22% |
+72,466
| New | +$409K |
|
|
SKINW
54
DELISTED
The Beauty Health Company Warrant expiring 5/4/2026
SKINW
| $88K | 0.05% |
+33,333
| New | +$88K |
|
|
ZYNE
55
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
| $44K | 0.02% |
+13,285
| New | +$44K |
|
56
ARK Genomic Revolution ETF
ARKG
$1.05B
| – | – |
0
| – | – |
|
|
VXRT
57
DELISTED
Vaxart
VXRT
| – | – |
0
| – | – |
|
58
SPDR S&P 500 ETF Trust
SPY
$656B
| – | – |
0
| – | – |
|
59
Solid Biosciences
SLDB
$448M
| – | – |
0
| – | – |
|
60
Syndax Pharmaceuticals
SNDX
$1.39B
| – | – |
0
| – | – |
|